Grifols, a CataloniaBio & HealthTech member, has completed the development of a TMA (Transcription-Mediated Amplification) molecular test that permits the detection of the SARS-CoV-2 virus in plasma, blood and respiratory samples, with a sensitivity equal or even superior to that of other molecular tests currently available, such as those based on PCR.
The company has developed the test in record time in a global coordinated effort of its facilities in San Diego, Barcelona and Bilbao, and has recently received the authorization of the Spanish Medicines and Medical Devices Agency (AEMPS). Grifols has a productive capacity of one million tests weekly.
According La Vanguardia, Spain will expand the diagnoses of Covid-19 with this new test in the coming weeks coinciding with the different phases of decontamination due to the pandemic.
You may also be interested in:
Grifols announces collaboration with US Government for a treatment against Covid-19
Comments